Cergutuzumab amunaleukin (CEA-IL2v) is a CEA-targeted IL-2 variant immunocytokine for combination cancer immunotherapy with immunostimulatory and anti-tumor activities for the study of solid cancers.

Cergutuzumab amunaleukin contains a single IL-2 variant (IL2V) part. The CD25 is abolished and blends to the high-end C-terminal. By removing the combination of CD25, Cergutuzumab amunaleukin can avoid priority activation of regulating T cells relative to immune effect cells. [1]
Cergutuzumab amunaleukin activated the NK cells and converted into a killing of CEA-positive colon cancer cell line LS180, accompanied by the increase in the release of granase B, IFNγ, and RANTES, and the upward increase of CD25 and CD69 NK cells. [1]

Among the tumor-free mice treated with 0.5 and 2 mg/kg Cergutuzumab amunaleukin (i.v.; Once) the strong amplification of CD8+ T and NK cells after treatment. [1]